BAFFR Gene (TNFRSF13C)

Gene Overview

flowchart TD
    TNFRSF13C["TNFRSF13C"] -->|"activates"| Als["Als"]
    TNFRSF13C["TNFRSF13C"] -->|"associated with"| Neurodegeneration["Neurodegeneration"]
    TNFRSF13C["TNFRSF13C"] -->|"associated with"| Ataxia["Ataxia"]
    TNFRSF13C["TNFRSF13C"] -->|"associated with"| Spinocerebellar_Ataxia["Spinocerebellar Ataxia"]
    TNFRSF13C["TNFRSF13C"] -->|"stabilizes"| Neurodegeneration["Neurodegeneration"]
    TNFRSF13C["TNFRSF13C"] -->|"activates"| HCRTR1["HCRTR1"]
    TNFRSF13C["TNFRSF13C"] -->|"associated with"| SCA3["SCA3"]
    TNFRSF13C["TNFRSF13C"] -->|"associated with"| ATXN3["ATXN3"]
    TNFRSF13C["TNFRSF13C"] -->|"activates"| CHRM4["CHRM4"]
    TNFRSF13C["TNFRSF13C"] -->|"activates"| MYO7A["MYO7A"]
    TNFRSF13C["TNFRSF13C"] -->|"activates"| ADRA2B["ADRA2B"]
    TNFRSF13C["TNFRSF13C"] -->|"activates"| GRM2["GRM2"]
    TNFRSF13C["TNFRSF13C"] -->|"encodes"| SCA3["SCA3"]
    TNFRSF13C["TNFRSF13C"] -->|"activates"| CRH["CRH"]
    style TNFRSF13C fill:#4fc3f7,stroke:#333,color:#000

Introduction

BAFFR (B cell Activating Factor Receptor, also known as TNFRSF13C, BR3, or CD268) is a critical member of the TNF receptor superfamily that plays an essential and non-redundant role in B cell survival, maturation, and homeostasis. Encoded by the TNFRSF13C gene on chromosome 22q12.1, BAFFR is expressed almost exclusively on B cells and is the sole receptor that mediates the survival and maturation functions of BAFF (B cell Activating Factor, also known as TNFSF13B or BLyS). Unlike TACI (TNFRSF13B) and BCMA (TNFRSF17), which also bind BAFF, BAFFR is uniquely required for the development and maintenance of mature B cells.

The discovery of BAFFR’s essential role in B cell biology came from studies of A/WySnJ mice, which carry a natural mutation in the Tnfrsf13c gene and exhibit profound B cell deficiency. This demonstrated that BAFFR is the critical receptor for BAFF-mediated survival signals, without which peripheral B cells undergo apoptosis. In humans, BAFFR deficiency causes severe antibody deficiency, highlighting its indispensable role in humoral immunity.

Beyond its well-established role in B cell biology, BAFFR has emerging relevance in neuroinflammatory and neurodegenerative diseases. B cells and antibodies are prominent features of central nervous system (CNS) autoimmune diseases, and BAFFR-expressing B cells likely contribute to disease pathogenesis through autoantibody production, cytokine secretion, and antigen presentation. Elevated BAFF levels have been detected in the cerebrospinal fluid (CSF) and brain tissue of patients with multiple sclerosis (MS), autoimmune encephalitis, and other neuroinflammatory conditions.

Molecular Biology and Structure

The TNFRSF13C gene spans approximately 7.5 kilobases and consists of 5 exons encoding the BAFFR protein. The gene is located on chromosome 22q12.1, a region not within the major histocompatibility complex (MHC), distinguishing it from many other immune-related genes.

The BAFFR protein is a type I transmembrane receptor with the following structural features:

Extracellular Domain: The extracellular region of BAFFR contains a single cysteine-rich domain (CRD) characteristic of TNF receptor family members, but notably simpler than TACI or other family members. This single CRD is sufficient for high-affinity BAFF binding. The extracellular domain forms a trimer, allowing binding to the trimeric BAFF ligand.

Transmembrane Domain: A single pass transmembrane helix anchors the receptor in the cell membrane.

Cytoplasmic Domain: The intracellular region is relatively short and contains motifs that mediate interactions with TRAF (TNF Receptor-Associated Factor) proteins, particularly TRAF3. Unlike TACI, BAFFR lacks a canonical TRAF-binding motif but still recruits TRAF proteins to activate downstream signaling.

BAFFR is unique among BAFF receptors in that it does not bind APRIL (A Proliferation-Inducing Ligand), which binds to TACI and BCMA. This ligand specificity contributes to BAFFR’s unique functional role in B cell survival.

Signaling Pathways

BAFFR activation triggers several downstream signaling cascades:

NF-κB Pathway

BAFFR signaling activates both canonical and non-canonical NF-κB pathways:

Canonical NF-κB: BAFFR engagement recruits TRAF proteins (primarily TRAF3) to the receptor complex, leading to activation of the IKK complex and subsequent IκB degradation. This releases NF-κB dimers (p50/p65, p50/c-Rel) to translocate to the nucleus and induce expression of survival genes including Bcl-2 and Bcl-xL.

Non-canonical NF-κB: BAFFR activates NF-κB-inducing kinase (NIK), which phosphorylates IKKα, leading to p100 processing to p52 and subsequent RelB activation. This pathway is particularly important for mature B cell survival.

TRAF3 Signaling

TRAF3 is a critical adaptor in BAFFR signaling. Under resting conditions, TRAF3 binds to BAFFR and promotes its degradation, limiting baseline NF-κB activation. Upon BAFF binding, TRAF3 is recruited and degraded, relieving this inhibition and allowing sustained NF-κB signaling.

Akt/mTOR Pathway

BAFFR can activate the Akt/mTOR pathway, which promotes cell survival and protein synthesis necessary for B cell maintenance.

Expression and Cellular Distribution

B Cell Expression

BAFFR is expressed almost exclusively on B cells:

• Transitional B cells: Low to moderate expression

• Mature naive B cells: High expression

• Memory B cells: High expression

• Plasma cells: Very low or absent (switched to BCMA expression)

• Germinal center B cells: High expression

BAFFR expression is regulated by B cell receptor (BCR) engagement and cytokine signals. The receptor is downregulated upon B cell activation and plasma cell differentiation.

Central Nervous System Expression

In the CNS, BAFFR is primarily expressed on:

• Infiltrating B cells: B cells that have entered the CNS in neuroinflammatory conditions

• Possible microglia: Some reports suggest BAFFR expression on microglia, though this is debated

• Perivascular cells: Some cells in the perivascular space may express BAFFR

BAFFR expression in the CNS is dramatically upregulated in neuroinflammatory conditions, driven by elevated BAFF levels in the CNS microenvironment.

Role in B Cell Biology

B Cell Survival and Homeostasis

BAFFR is absolutely essential for the survival of mature peripheral B cells. The BAFF/BAFFR axis provides critical survival signals that:

• Upregulate anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1)

• Promote metabolic fitness

• Maintain B cell numbers in the periphery

Without BAFFR signaling (as in BAFFR-deficient mice or humans), mature B cells undergo apoptosis, leading to severe B cell lymphopenia and hypogammaglobulinemia.

B Cell Maturation

BAFFR is required for the progression of transitional B cells to mature naive B cells. BAFFR signaling supports:

• Selection of B cells with appropriate BCRs

• Maturation of transitional type 2 (T2) B cells to mature B cells

• Maintenance of marginal zone B cells

Germinal Center Response

BAFFR plays important roles in the germinal center reaction:

• Supports survival of germinal center B cells

• Contributes to class switch recombination

• Promotes plasma cell differentiation

Antibody Production

BAFFR is required for optimal antibody responses:

• T-dependent antibody responses

• T-independent antibody responses

• Class switching to IgG, IgA, and IgE

Disease Associations

Multiple Sclerosis (MS)

MS is an autoimmune demyelinating disease characterized by inflammation, demyelination, and neurodegeneration in the CNS. B cells and antibodies are central to MS pathogenesis, as evidenced by:

• Oligoclonal bands in CSF (intrathecal antibody production)

• B cell and plasma cell infiltrates in MS lesions

• Demyelinating antibodies

• Efficacy of B cell-depleting therapies (rituximab, ocrelizumab)

BAFFR in MS:

• BAFF is dramatically elevated in MS CSF (10-50 fold increase)

• BAFF is expressed in MS brain lesions by astrocytes and microglia

• BAFFR-expressing B cells are present in MS lesions

• BAFFR supports survival of autoantibody-producing B cells in the CNS

Therapeutic targeting: BAFF antagonists (belimumab) and BAFFR-targeted approaches are being explored for MS treatment.

Autoimmune Encephalitis (AE)

Autoimmune encephalitis is a group of disorders characterized by autoantibodies against neuronal surface antigens, leading to brain inflammation and dysfunction.

BAFFR in AE:

• BAFF is elevated in AE CSF

• BAFFR-expressing B cells are present in the CNS

• BAFFR supports survival of autoantibody-producing cells

• B cell depletion is effective in many AE subtypes

Neuroinflammatory Disorders

BAFFR plays roles in various neuroinflammatory conditions:

• Neuromyelitis optica spectrum disorder (NMOSD): B cells and BAFF are prominent

• Myasthenia gravis: Anti-AChR antibodies; BAFF levels correlate with disease

• MOG antibody disease: B cell-mediated demyelination

Alzheimer’s Disease and Parkinson’s Disease

Emerging evidence suggests BAFF/BAFFR involvement in neurodegenerative diseases:

• BAFF is elevated in AD and PD brains

• B cells and antibodies are found in AD and PD tissue

• BAFFR may support neurotoxic B cell responses

• BAFF can have direct effects on neurons through receptors other than BAFFR

BAFFR versus TACI: Distinct but Complementary Roles

While both BAFFR and TACI bind BAFF, they have distinct and non-overlapping functions:

BAFFR is the primary receptor for B cell survival, while TACI is more important for class switching and plasma cell function. Both receptors can contribute to disease when dysregulated.

Therapeutic Implications

BAFF/BAFFR Pathway Inhibition

Several therapeutic approaches target this pathway:

BAFF inhibitors:

• Belimumab: Anti-BAFF monoclonal antibody, approved for systemic lupus erythematosus (SLE)

• Tabalumab: Anti-BAFF antibody tested in SLE, MS, and other conditions

BAFFR-targeted approaches:

• BAFFR antagonists in development

• BAFFR-Fc fusion proteins to sequester BAFF

BCMA/TACI-Fc fusion proteins:

• Atacicept: TACI-Fc binds BAFF and APRIL, affecting both BAFFR and TACI pathways

Clinical Applications

In neuroinflammatory diseases:

• Belimumab has been tested in MS with mixed results

• Atacicept showed promise in some MS trials

• B cell depletion (rituximab, ocrelizumab) is highly effective in MS and AE

Considerations:

• BAFFR is essential for B cell survival; complete blockade may cause immunodeficiency

• Partial inhibition may be sufficient to modulate pathogenic B cells

• Combination approaches with other immunomodulatory agents

Cross-Linking and Related Pages

• BAFF (TNFSF13B) Gene

• TACI (TNFRSF13B) Gene

• BCMA (TNFRSF17) Gene

• B Cells

• NF-κB Signaling

• Neuroinflammation

• Multiple Sclerosis

• Autoimmune Encephalitis

• Common Variable Immunodeficiency

See Also

• TNF Receptor Superfamily

• B Cell Development

• BAFF Signaling

• Antibody-Mediated Immunity

• Cytokine Signaling

External Links

• NCBI Gene - TNFRSF13C

• UniProt - Q9Y239

• Ensembl - TNFRSF13C

• GeneCards - TNFRSF13C

• OMIM - TNFRSF13C